Yanan Ren

Preclinical evaluation and first in human study of Al18F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer

Jiayue Liu, Xing Yang, Hua Zhu, 2022, Frontiers in Oncology.

Construction and Preclinical Evaluation of a 124/125I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer.

Y. Yao, Nan Li, Hua Zhu, 2022, Molecular pharmaceutics.

Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging.

Y. Yao, Hua Zhu, Zhi Yang, 2023, Molecular pharmaceutics.

An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer

Hua Zhu, Zhi Yang, Te-li Liu, 2022, Pharmaceuticals.

One-Minute Iodine Isotope Labeling Technology Enables Noninvasive Tracking and Quantification of Extracellular Vesicles in Tumor Lesions and Intact Animals.

Y. Yao, Xiangyu Gao, Chuanke Zhao, 2023, Molecular pharmaceutics.

68Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent

M. Pomper, Jinming Zhang, Xiaojun Zhang, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Construction and preclinical evaluation of a zirconium-89 labelled monoclonal antibody targeting PD-L2 in lung cancer.

Te-li Liu, Xingguo Hou, Qian Zhang, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Unique role of molecular imaging probes for viral infection

Te-li Liu, Xingguo Hou, Qian Zhang, 2024, TrAC Trends in Analytical Chemistry.

An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.

Xingguo Hou, Lei Xia, Pei Wang, 2023, International journal of pharmaceutics.

First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma.

Xuesong Li, Xing Yang, S. Rowe, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.